Vanguard Group’s Processa Pharmaceuticals PCSA Stock Holding History

Vanguard Group’s Portfolio PCSA Stock Details PCSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$67.9K	Buy	23,586 +12,058	+105%	+$84.2K	﹤0.01%	4210
2025 Q3	$55.3K	Buy	11,528 +10,551	+1,080%	+$55.7K	﹤0.01%	4288
2025 Q2	$5.01K	Hold	977	–	–	﹤0.01%	4266
2025 Q1	$9.04K	Hold	977	–	–	﹤0.01%	4258
2024 Q4	$21.7K	Hold	977	–	–	﹤0.01%	4256
2024 Q3	$33.5K	Hold	977	–	–	﹤0.01%	4272
2024 Q2	$54.7K	Hold	977	–	–	﹤0.01%	4283
2024 Q1	$57.8K	Buy	977 +508	+108%	+$40.2K	﹤0.01%	4303
2023 Q4	$78.5K	Sell	469 -220	-32%	-$49.1K	﹤0.01%	4327
2023 Q3	$86.2K	Sell	689 -34	-5%	-$6.42K	﹤0.01%	4361
2023 Q2	$180K	Hold	723	–	–	﹤0.01%	4325
2023 Q1	$181K	Sell	723 -25	-3%	-$10.1K	﹤0.01%	4333
2022 Q4	$411K	Buy	748 +1	+0.1%	+$966	﹤0.01%	4155
2022 Q3	$845K	Hold	747	–	–	﹤0.01%	4055
2022 Q2	$1.05M	Hold	747	–	–	﹤0.01%	4071
2022 Q1	$1.13M	Hold	747	–	–	﹤0.01%	4169
2021 Q4	$1.83M	Sell	747 -1	-0.1%	-$3.1K	﹤0.01%	4077
2021 Q3	$3.2M	Buy	748 +2	+0.3%	+$6.83K	﹤0.01%	3889
2021 Q2	$3.06M	Buy	746 +431	+137%	+$1.67M	﹤0.01%	3829
2021 Q1	$1.72M	Buy	315 +258	+453%	+$1.2M	﹤0.01%	3898
2020 Q4	$189K	Buy	+57	New	+$158K	﹤0.01%	4093

Other funds holding PCSA

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Vanguard Group's PCSA Position: Q4 2025 in Review

Vanguard Group increased its Processa Pharmaceuticals (PCSA) stake by 105% in Q4 2025, buying an estimated $84.2K and bringing the position to 23,586 shares worth $67.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4210.

Vanguard Group first reported a position in PCSA in Q4 2020 and has held it in 21 quarters since. The position peaked at $3.2M in Q3 2021. 10 funds tracked by Wall St. Rank hold PCSA as of Q4 2025.

Vanguard Group held 23,586 shares of Processa Pharmaceuticals worth $67.9K as of Q4 2025.
Vanguard Group bought 12,058 Processa Pharmaceuticals shares in Q4 2025, an estimated $84.2K.
Processa Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4210 holding.
Vanguard Group first reported a position in Processa Pharmaceuticals in Q4 2020 and has held it in 21 quarters since.
Vanguard Group's Processa Pharmaceuticals position peaked at $3.2M in Q3 2021.
10 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.